Summary Fallopian tube carcinoma (FTC) is a rare but lethal gynaecological malignancy. Four out of seven FTCs were identified with three point missense mutations, one single base deletion and one silent point mutation in the p53 gene. Genital-type HPV sequences were not detected. The S-phase fraction of tumours with mutant and wild-type p53 was 25.74% (median) and 12.55% (median) respectively.
Primary fallopian tube carcinoma (FTC) is an aggressive, malignant tumour of the female genital tract with an unfavourable prognosis and an approximately 10% 5 year survival in the later stages (Eddy et al., 1984; Rose et al., 1990; Rosen et al., 1993 ). FTCs are rare, constituting about 1% of all female genital tract cancers. The vast majority represent adenocarcinomas and show histopathological similarities to epithelial ovarian cancer. In non-familial ovarian cancer, alteration of the p53 tumour-suppressor gene by somatic mutation is the most common single-gene alteration identified so far (Marks et al., 1991; Okamoto et al., 1991; Tsao et al., 1991; Kupryjanczyk et al., 1993; Milner et al., 1993; Runnebaum et al., 1994a; Runnebaum et al., 1995a) . Wild-type p53 is a potent suppressor of tumorigenesis in different tumour types (Eliyahu et al., 1989; Baker et al., 1990; Cheng et al., 1992; Runnebaum et al., 1994c; Runnebaum and Kreienberg 1995) . p53 acts as a transcription factor (Kern et al., 1991; Unger et al., 1992) regulating cellular functions such as DNA damage response (Kastan et al., 1991 (Kastan et al., , 1992 , induction of apoptosis by transactivating Bax and transrepressing Bcl-2 (Miyashita et al., 1994; Miyashita and Reed, 1995) or inducing G1 cell cycle arrest by transactivating p2iWAFI/CIPI (Lowe and Ruley 1993; Yonish-Rouach et al., 1993; Runnebaum et al., 1995b) . A p53 mutation in FTC has first been identified in the cell line FT-MZ-1 established in our laboratory (Runnebaum et al., 1994b extracted from the paraffin-embedded formalin-fixed sections as described previously (Runnebaum et al., 1991 (Runnebaum et al., , 1994b (Table II) . Two mutations were identified in tumour no. 777, one silent point mutation in exon 8 not leading to an amino acid change and one single base deletion in exon 6 shifting the reading frame (Figure 1) (Eddy et al., 1984; Rosen et al., 1993; Lacy et al., 1995) . The tumours in this study were papillary adenocarcinomas representative for FTC. The tumours were metastatic at the time of diagnosis with FIGO stages IIA and IIIC (Nordin, 1994) . In four out of seven FTCs, mutations in the p53 tumour-suppressor gene were identified. The four point mutations were transition mutations, three of which changed the primary amino acid sequence. p53 transition mutations have frequently been found in other carcinoma types such as ovarian cancer, breast cancer and colon cancer and are considered to occur spontaneously. The point mutation in tumour no. 777 occurred at the third base position of codon 267 as a silent mutation. In the same tumour, an additional p53 mutation was found. The single base deletion in codon 194 leads to a frame shift. Small deletions could be caused by DNA replication errors and appear to occur relatively frequently in ovarian cancer (Okamoto et al., 1991; Milner et al., 1993; Runnebaum et al., 1994a) . The loss of heterozygosity (LOH) rate at the p53 gene locus on chromosome arm 17p is not known for FTC. In various tumours the rate of LOH at this locus exceeds the rate of p53 mutations. Two out of four FTCs with mutant p53, however, remained heterozygous at the p53 locus.
The identified mutations were located in the 'core region', which comprises codons 102 to 292 of the p53 gene (Cho et al., 1994 (El-Deiry et al., 1993; Harper et al.. 1993) . p2lWAFI CIPI complexes with and inhibits factors essential for cell cycle progression at the G, checkpoint and DNA replication, cyclin-dependent kinases and the proliferating cell nuclear antigen (PCNA) (Chen et al.. 1995 : Luo et al.. 1995 . In the p53 heterozygous tumour no. 339. wild-type p53 may be inactivated in the presence of a dominant negative mutant protein possibly sequestering the wild-type protein by oligomerisation (Clore et al.. 1994) .
In a small number of fallopian tube cancers. we have demonstrated that the p53 tumour-suppressor gene can be mutated with accumulation of aberrant p53 protein. FTCs with a p53 mutation may present with a higher S and a lower G, Go fraction. Larger studies will define the role of p53 mutation and cell cycle parameters as indicators of clinical outcome. Because of the rarity of FTC. such studies could best be performed in multicentre cooperative study groups.
